| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | AJ1-11095 (AJX-101 study) Myelofibrosis (patients who have failed a type I JAK2 inhibitor) | Phase 1 | 5% AJ1-11095, also referred to as AJX-101, is an early-stage program targeting myelofibrosis in patients who have experienced failure with a type I JAK2 inhibitor. However, due to the lack of verifiable public trial, regulatory, or designation data, any specific probability of approval, market figures, or designation status would be speculative rather than evidence-based. The regulatory designations for myelofibrosis in this context indicate that AJ1-11095 does not currently hold any of the following statuses: Fast Track Designation, Orphan Drug Designation, Breakthrough Therapy Designation, Priority Review, or Accelerated Approval, as outlined in the provided data. Market analysis reveals that while the unmet need in this setting is significant, the specific market size remains unknown due to the absence of supporting sources. Myelofibrosis following the failure of a type I JAK2 inhibitor is widely recognized as a high-unmet-need area, characterized by persistent splenomegaly, constitutional symptoms, cytopenias, and limited treatment options. However, without concrete data, a precise global market-size estimate cannot be provided. The drug classification for AJ1-11095 is also currently unknown. The estimated probability of approval for AJ1-11095 stands at 5.0%. This figure reflects the substantial uncertainty surrounding the asset, particularly given its early development stage. Key risks associated with this program include the absence of a verifiable clinical dataset, which leaves the efficacy and safety of AJ1-11095 unproven. The high-risk nature of early-phase development, especially in a refractory myelofibrosis population, adds to the uncertainty. Furthermore, competitive and regulatory risks are significant, as the myelofibrosis landscape is populated with established JAK-inhibitor therapies, and regulatory bodies typically require compelling evidence of benefit in terms of spleen/symptom improvement and survival. Looking ahead, there are several upcoming catalysts for AJ1-11095, including an initial clinical readout, a Phase 1/2 expansion update, and potential regulatory interactions or designation announcements. However, the timing for these events has not been disclosed. In summary, AJ1-11095 represents an early-stage program in a challenging clinical setting. Given the lack of verifiable information regarding the asset’s modality, sponsor history, trial design, and regulatory designations, the program must be regarded as unvalidated from an approval standpoint. While the myelofibrosis setting after JAK inhibitor failure presents a meaningful unmet need, the absence of confirmed clinical data limits the ability to classify the asset definitively. The probability of approval is low by base-rate standards, particularly as the program is currently in Phase 1. Early-phase oncology and hematology programs often face high attrition rates due to inadequate efficacy or dose-limiting toxicity. In the context of myelofibrosis, differentiation typically requires evidence of spleen volume reduction, symptom improvement, and management of anemia or cytopenia. Without reported response rates or other critical efficacy data, the basis for a higher probability of approval is lacking. In conclusion, the estimated probability of approval for AJ1-11095 remains at 5.0%, reflecting the early-stage nature of the asset and the substantial unknowns that accompany it, rather than an assertion regarding the intrinsic quality of the drug. Read More | Small Molecules | Hematologic System | ||
Phase 1 data readout example | AJ1-11095 (AJX-101 study) Myelofibrosis (patients who have failed a type I JAK2 inhibitor) | Phase 1 | 5% AJ1-11095, also referred to as AJX-101, is an early-stage program targeting myelofibrosis in patients who have experienced failure with a type I JAK2 inhibitor. However, due to the lack of verifiable public trial, regulatory, or designation data, any specific probability of approval, market figures, or designation status would be speculative rather than evidence-based. The regulatory designations for myelofibrosis in this context indicate that AJ1-11095 does not currently hold any of the following statuses: Fast Track Designation, Orphan Drug Designation, Breakthrough Therapy Designation, Priority Review, or Accelerated Approval, as outlined in the provided data. Market analysis reveals that while the unmet need in this setting is significant, the specific market size remains unknown due to the absence of supporting sources. Myelofibrosis following the failure of a type I JAK2 inhibitor is widely recognized as a high-unmet-need area, characterized by persistent splenomegaly, constitutional symptoms, cytopenias, and limited treatment options. However, without concrete data, a precise global market-size estimate cannot be provided. The drug classification for AJ1-11095 is also currently unknown. The estimated probability of approval for AJ1-11095 stands at 5.0%. This figure reflects the substantial uncertainty surrounding the asset, particularly given its early development stage. Key risks associated with this program include the absence of a verifiable clinical dataset, which leaves the efficacy and safety of AJ1-11095 unproven. The high-risk nature of early-phase development, especially in a refractory myelofibrosis population, adds to the uncertainty. Furthermore, competitive and regulatory risks are significant, as the myelofibrosis landscape is populated with established JAK-inhibitor therapies, and regulatory bodies typically require compelling evidence of benefit in terms of spleen/symptom improvement and survival. Looking ahead, there are several upcoming catalysts for AJ1-11095, including an initial clinical readout, a Phase 1/2 expansion update, and potential regulatory interactions or designation announcements. However, the timing for these events has not been disclosed. In summary, AJ1-11095 represents an early-stage program in a challenging clinical setting. Given the lack of verifiable information regarding the asset’s modality, sponsor history, trial design, and regulatory designations, the program must be regarded as unvalidated from an approval standpoint. While the myelofibrosis setting after JAK inhibitor failure presents a meaningful unmet need, the absence of confirmed clinical data limits the ability to classify the asset definitively. The probability of approval is low by base-rate standards, particularly as the program is currently in Phase 1. Early-phase oncology and hematology programs often face high attrition rates due to inadequate efficacy or dose-limiting toxicity. In the context of myelofibrosis, differentiation typically requires evidence of spleen volume reduction, symptom improvement, and management of anemia or cytopenia. Without reported response rates or other critical efficacy data, the basis for a higher probability of approval is lacking. In conclusion, the estimated probability of approval for AJ1-11095 remains at 5.0%, reflecting the early-stage nature of the asset and the substantial unknowns that accompany it, rather than an assertion regarding the intrinsic quality of the drug. Read More | Small Molecules | Hematologic System | ||
Phase 1 data readout example | AJ1-11095 (AJX-101 study) Myelofibrosis (patients who have failed a type I JAK2 inhibitor) | Phase 1 | 5% AJ1-11095, also referred to as AJX-101, is an early-stage program targeting myelofibrosis in patients who have experienced failure with a type I JAK2 inhibitor. However, due to the lack of verifiable public trial, regulatory, or designation data, any specific probability of approval, market figures, or designation status would be speculative rather than evidence-based. The regulatory designations for myelofibrosis in this context indicate that AJ1-11095 does not currently hold any of the following statuses: Fast Track Designation, Orphan Drug Designation, Breakthrough Therapy Designation, Priority Review, or Accelerated Approval, as outlined in the provided data. Market analysis reveals that while the unmet need in this setting is significant, the specific market size remains unknown due to the absence of supporting sources. Myelofibrosis following the failure of a type I JAK2 inhibitor is widely recognized as a high-unmet-need area, characterized by persistent splenomegaly, constitutional symptoms, cytopenias, and limited treatment options. However, without concrete data, a precise global market-size estimate cannot be provided. The drug classification for AJ1-11095 is also currently unknown. The estimated probability of approval for AJ1-11095 stands at 5.0%. This figure reflects the substantial uncertainty surrounding the asset, particularly given its early development stage. Key risks associated with this program include the absence of a verifiable clinical dataset, which leaves the efficacy and safety of AJ1-11095 unproven. The high-risk nature of early-phase development, especially in a refractory myelofibrosis population, adds to the uncertainty. Furthermore, competitive and regulatory risks are significant, as the myelofibrosis landscape is populated with established JAK-inhibitor therapies, and regulatory bodies typically require compelling evidence of benefit in terms of spleen/symptom improvement and survival. Looking ahead, there are several upcoming catalysts for AJ1-11095, including an initial clinical readout, a Phase 1/2 expansion update, and potential regulatory interactions or designation announcements. However, the timing for these events has not been disclosed. In summary, AJ1-11095 represents an early-stage program in a challenging clinical setting. Given the lack of verifiable information regarding the asset’s modality, sponsor history, trial design, and regulatory designations, the program must be regarded as unvalidated from an approval standpoint. While the myelofibrosis setting after JAK inhibitor failure presents a meaningful unmet need, the absence of confirmed clinical data limits the ability to classify the asset definitively. The probability of approval is low by base-rate standards, particularly as the program is currently in Phase 1. Early-phase oncology and hematology programs often face high attrition rates due to inadequate efficacy or dose-limiting toxicity. In the context of myelofibrosis, differentiation typically requires evidence of spleen volume reduction, symptom improvement, and management of anemia or cytopenia. Without reported response rates or other critical efficacy data, the basis for a higher probability of approval is lacking. In conclusion, the estimated probability of approval for AJ1-11095 remains at 5.0%, reflecting the early-stage nature of the asset and the substantial unknowns that accompany it, rather than an assertion regarding the intrinsic quality of the drug. Read More | Small Molecules | Hematologic System |
Recent Updates
Recently added Catalysts
Eli Lilly and Company$1,160.59
+29.06 (+2.57%)
A 94Pipeline Score Overvalued Pharma · Commercial
Market Cap
1002.95 B
EPS
27.82
P/E Ratio
38.34 $
Value Trade
2.87 B
SEC Financials
Q1 2026Dilution Risk
Revenue
19.80 B
R&D Expenses
3.51 B
Operating CF
5.33 B
Total Assets
116.58 B
Total Liabilities
116.58 B
Equity
31.20 B
D/E Ratio
12,345
5.76 %
Week
17.5 %
1 Month
4.02 %
3 Month
2.31 %
6 Month
432.5 %
5 Year
37,819.33 %
All Time
Cash Data
Cash Position
5.28 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
2.53 M
52 Week Range
623.78 - 1,133.95
% held by Insiders
10.05 %
% held by Institutions
74.79 %
Enterprise Value
1041.04 B
Total Shares
944.82 M
Short %
1 %
Float Shares
851.28 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
A94
Pipeline Score $287.8B
Pipeline ValueOvervalued
Valuation Signal374
Drugs Scored0.3x
rNPV / MCap Top 100%
Large Pharma (rank 1 of 905)
Percentile RankEli Lilly and Company earns an A-grade pipeline score (94/100), with $287.8B risk-adjusted pipeline value, led by LY2189265 in Diabetes Mellitus, Type 2 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2189265 Monoclonal antibody | Diabetes Mellitus, Type 2 | Phase 3 | NCT01408888 | 67% | $17.4B | COMPLETED | 8,059 | - | - | Apr 1, 2012 | - | Oct 7, 2014 |
LLY Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Zepbound (tirzepatide) | obesity,overweight with weight-related medical conditions,moderate-to-severe obstructive sleep apnea | Phase 2 | 2025-06-16 | |||
Zepbound (tirzepatide) | obesity,overweight with weight-related medical conditions,moderate-to-severe obstructive sleep apnea | Phase 2 | 2025-06-16 | |||
Zepbound (tirzepatide) | obesity,overweight with weight-related medical conditions,moderate-to-severe obstructive sleep apnea | Phase 2 | 2025-06-16 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LLY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV 386.78 M (-36.11%) | Shares Owned 420.52 K (-25.35%) | Activity Avg Price $0 |
|---|---|---|---|---|
INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.7 % (-36.4 %) | 13.80 M | 15.00 K | -25% ( -5.00 K) |
INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.7 % (-36.4 %) | 13.80 M | 15.00 K | -25% ( -5.00 K) |
INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.7 % (-36.4 %) | 13.80 M | 15.00 K | -25% ( -5.00 K) |
Eli Lilly and Company (LLY) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
LLY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LLY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LLY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LLY Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LLY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Eli Lilly and Company (LLY) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How LLY ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Obesity | #1 of 33 | Retatrutide | AMGN NVO RYTM | $22.52B | 0.95 | ||
| Type 2 Diabetes | #1 of 33 | Retatrutide | AMGN NVO PFE | $25.4B | 0.97 | ||
| Osteoarthritis | #1 of 13 | Eloralintide | PCRX NVO BVS | $6.0B | 0.97 | ||
| Atopic Dermatitis | #1 of 25 | Baricitinib + corticosteroid | ABBV PFE SNY | $20.76B | 0.92 | ||
| Type 1 Diabetes | #1 of 19 | Tirzepatide | NVO SNY DXCM ·dev | $3.5B | 0.93 | ||
| Chronic Pain | #1 of 16 | Retatrutide | BSX ·dev CELZ ZBH ·dev | $91.35B | 0.96 | ||
| Sleep Disorders | #1 of 14 | Retatrutide | NVO AMGN INSP | $3.95B | 0.96 | ||
| General Cardiovascular Diseases | #1 of 16 | Retatrutide | UTHR EW ·dev ABT ·dev | — | 0.96 | ||
| Hypertension | #1 of 16 | Orforglipron | ALNY MLYS UTHR | $9.41B | 0.97 | ||
| Thyroid Cancer | #1 of 12 | Selpercatinib + Cabozantinib + Vandetanib | NVS EXEL MRK | $4.2B | 0.95 | ||
| Peripheral Artery Disease | #1 of 17 | Orforglipron | REGN ABT ·dev MMSI | — | 0.95 | ||
| Substance Use Disorders | #1 of 8 | LY3537031 | ALT CMND HBIO | — | 0.95 | ||
| Dyslipidemia | #1 of 9 | Lepodisiran | MRK NVS NAMS | $16.03B | 0.86 | ||
| Urinary Disorders | #1 of 4 | Orforglipron | INMD BDX ·dev ATLN | — | 0.98 | ||
| Psychiatric Disorders | #1 of 3 | Donanemab + Dexamethasone | MASI HCSG | — | 0.93 | ||
| Neuropathic Pain | #1 of 6 | LY3848575 | DWTX SGMO UBX | $8.73B | 0.93 | ||
| Hormonal Disorders | #1 of 5 | Abemaciclib + Abiraterone + Prednisone or Prednisolone | AZN ABCL BMY | — | 0.91 | ||
| Addiction | #1 of 1 | Brenipatide | — | $1.5B | 0.97 | ||
| Allergic Rhinitis | #1 of 3 | LY3650150 + Standard therapy for INCS | PLRZ REGN | $16.1B | 0.95 | ||
| Hearing Loss | #1 of 2 | AAVAnc80-hOTOF via Akouos Delivery Device | COCH | $7.53B | 0.88 | ||
| Lymphoma | #2 of 69 | Pirtobrutinib + Idelalisib + Bendamustine + Rituximab | REGN MRK AZN | $8.52B | 0.85 | ||
| Leukemia | #2 of 64 | Pirtobrutinib + Idelalisib + Bendamustine + Rituximab | AMGN AZN MRK | $4.28B | 0.84 | ||
| Rheumatoid Arthritis | #2 of 28 | Baricitinib | ABBV BMY JNJ | $4.2B | 0.95 | ||
| Chronic Kidney Disease | #2 of 27 | Retatrutide | AZN NVO FMS | $96.33B | 0.91 | ||
| Crohn's Disease | #2 of 15 | Mirikizumab | SNY ABBV JNJ | $12.67B | 0.87 | ||
| Alzheimer's Disease | #2 of 24 | Donanemab + Dexamethasone | BMY BIIB ANVS | $6.49B | 0.93 | ||
| General Hematological Disorders | #2 of 4 | LY2784544 | VRTX AZN AAPG | — | 0.97 | ||
| Uveitis | #2 of 5 | Baricitinib + Adalimumab | ROIV ANIP REGN | $1.2B | 0.85 | ||
| Ovarian Cancer | #3 of 61 | Sofetabart Mipitecan + Paclitaxel + Topotecan + Gemcitabine + Pegylated liposomal doxorubicin + MIRV + Bevacizumab + Carboplatin | MRK AZN ABBV | $4.0B | 0.87 | ||
| Ulcerative Colitis | #3 of 17 | Mirikizumab | SNY JNJ ABBV | $6.5B | 0.86 | ||
| Sarcoma | #3 of 31 | Abemaciclib + Irinotecan + Temozolomide | NVS INTS PFE | $1.75B | 0.9 | ||
| Cholangiocarcinoma | #3 of 24 | Ramucirumab + Merestinib + Cisplatin + Gemcitabine | AZN JAZZ TNGX | $0.62B | 0.92 | ||
| Atherosclerosis | #3 of 15 | Lepodisiran | NVO NVS AMGN | — | 0.86 | ||
| Migraine | #3 of 5 | Galcanezumab | ABBV PFE AMGN | $7.02B | 0.96 | ||
| NASH / MASH | #3 of 11 | Tirzepatide + Retatrutide | MDGL NVO REGN | $7.87B | 0.93 | ||
| Skin Disorders | #3 of 15 | Baricitinib | INCY SNY AMGN | — | 0.92 | ||
| Pediatric Conditions | #3 of 8 | Ramucirumab + Cyclophosphamide + Vinorelbine + Gemcitabine + Docetaxel + Abemaciclib + Irinotecan + Temozolomide | BCRX CYTK SUPN | $28.2B | 0.91 | ||
| Chronic Rhinosinusitis | #3 of 4 | LY3650150 + Standard therapy for INCS | SNY AZN REGN | $3.11B | 0.98 | ||
| Breast Cancer | #4 of 94 | Abemaciclib + Standard Adjuvant Endocrine Therapy | MRK AZN GILD | $10.85B | 0.9 | ||
| Alopecia | #4 of 12 | Baricitinib | PFE MANE ABBV | $10.76B | 0.92 | ||
| Non-Small Cell Lung Cancer | #5 of 88 | Selpercatinib + Carboplatin + Cisplatin + Pemetrexed + Pembrolizumab | MRK AMGN AZN | $28.1B | 0.91 | ||
| Prostate Cancer | #5 of 53 | Abemaciclib + Abiraterone + Prednisone or Prednisolone | MRK AZN PFE | $25.12B | 0.78 | ||
| Cervical Cancer | #5 of 31 | LY4101174 | AZN MRK PFE | $2.8B | 0.94 | ||
| Bipolar Disorder | #5 of 12 | Brenipatide | BMY ABBV ALKS | $10.5B | 0.95 | ||
| Bladder Cancer | #6 of 47 | Vepugratinib + EV + Pembrolizumab | AZN BMY JNJ | $0.33B | 0.91 | ||
| Psoriasis | #6 of 15 | Ixekizumab + Tirzepatide | JNJ BMY ABBV | $26.66B | 0.97 | ||
| Psoriatic Arthritis | #6 of 13 | Ixekizumab + Adalimumab | JNJ ABBV BMY | — | 0.88 | ||
| Schizophrenia | #6 of 15 | Brenipatide | NBIX BMY ALKS | $2.5B | 0.98 | ||
| Brain Tumors | #7 of 45 | Abemaciclib + Temozolomide | NVCR JAZZ DAWN | $3.55B | 0.87 | ||
| Esophageal Cancer | #7 of 39 | Ramucirumab + Paclitaxel | MRK AZN ONC | $1.85B | 0.9 | ||
| Neuropathy | #7 of 20 | LY3848575 | VRTX ARGX SNY | $8.0B | 0.94 | ||
| Hidradenitis Suppurativa | #7 of 13 | Eltrekibart | ABBV INCY NVS | $1.7B | 0.95 | ||
| Dyslipidemia / Hypercholesterolemia | #7 of 14 | Solbinsiran | NVS ARWR MRK | — | 0.89 | ||
| Parkinson's Disease | #8 of 22 | LY3884961 + Methylprednisolone + Sirolimus | SUPN PRTA BHVN | $5.96B | 0.93 | ||
| Multiple Sclerosis | #9 of 20 | LY3541860 | SNY NVS BIIB | $31.92B | 0.9 | ||
| Lung Cancer | #10 of 79 | Ramucirumab + Erlotinib + Gefitinib + Osimertinib | MRK GILD AMGN | $28.1B | 0.91 | ||
| Endometrial Cancer | #10 of 48 | LY3537982 + Pembrolizumab + Cetuximab + Pemetrexed + Cisplatin + Carboplatin | MRK AZN GILD | $31.09B | 0.93 | ||
| Major Depressive Disorder | #10 of 31 | Brenipatide | CMPS NBIX JNJ | $12.0B | 0.95 | ||
| Asthma | #10 of 16 | Brenipatide | NVS TEVA GSK | $30.84B | 0.95 | ||
| Myeloproliferative Neoplasms | #10 of 14 | LY3410738 + Venetoclax + Azacitidine | BMY ABBV NVS | — | 0.84 | ||
| ALS | #10 of 15 | 89Zr-DFO-AP-101 | AMLX BIIB IONS | $1.2B | 0.8 | ||
| Gastric Cancer | #11 of 49 | Ramucirumab + Paclitaxel | AZN ONC JAZZ | $6.74B | 0.84 | ||
| Chronic Liver Disease | #11 of 27 | Lepodisiran | GSK GILD MDGL | $19.9B | 0.97 | ||
| Pancreatic Cancer | #12 of 73 | LY4101174 | RVMD RCUS AZN | $3.7B | 0.93 | ||
| Thrombocytopenia | #12 of 18 | Pirtobrutinib | NVS TAK ARGX | $1.85B | 0.89 | ||
| Colorectal Cancer | #13 of 82 | LY2157299 + Capecitabine + Fluorouracil | ABBV BMY MRK | $7.68B | 0.91 | ||
| Myelodysplastic Syndromes | #14 of 33 | LY3410738 + Venetoclax + Azacitidine | BMY ABBV TAK | $2.5B | 0.84 | ||
| Systemic Lupus Erythematosus | #15 of 32 | LY4298445 | BIIB VTRS BMY | $2.78B | 0.99 | ||
| Rare Metabolic Disorders | #17 of 30 | LY3884961 + Methylprednisolone + Sirolimus + Prednisone | AZN SNY TVTX | $21.15B | 0.76 | ||
| Multiple Myeloma | #19 of 27 | LOXO-338 + Pirtobrutinib | JNJ ABBV BMY | $23.78B | 0.92 | ||
| Head and Neck Cancer | #21 of 63 | LY4101174 | AZN GSK MRK | $10.2B | 0.95 | ||
| Rare Genetic Disorders | #47 of 61 | Selpercatinib | BMRN ASND NVS | — | 0.89 |